The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Pembrolizumab plus AVD in cHL: long-term follow-up of a Phase II study
Ryan Lynch, MD, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, presents updated long-term follow-up data of a Phase II trial (NCT03331341) investigating the use of pembrolizumab plus AVD chemotherapy (doxorubicin, vinblastine, and dacarbazine) for the treatment of patients with previously untreated classical Hodgkin lymphoma (cHL) of any stage. This therapeutic strategy leads to durable remissions in patients, including those with high-risk H2 genetic subtypes and those in advanced stages of disease. Dr Lynch also comments on the use of PET/CT for response assessment in these patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Seagen Inc., Rapt, Cyteir, Incyte, Genentech, Bayer, TG Therapeutics, Merck
Consultancy: Cancer Study Group, SeaGen, Foresight Diagnostics, Abbvie
